See more : Nexus AG (0FGL.L) Income Statement Analysis – Financial Results
Complete financial analysis of Athersys, Inc. (ATHX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athersys, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sunward Intelligent Equipment Co., Ltd. (002097.SZ) Income Statement Analysis – Financial Results
- Black Box Entertainment Ltd. (BBOE) Income Statement Analysis – Financial Results
- Mahindra & Mahindra Limited (M&M.NS) Income Statement Analysis – Financial Results
- Gage Growth Corp. (GAEGF) Income Statement Analysis – Financial Results
- Stillfront Group AB (publ) (SF.ST) Income Statement Analysis – Financial Results
Athersys, Inc. (ATHX)
About Athersys, Inc.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 5.51M | 1.43M | 5.52M | 23.74M | 2.84M | 16.24M | 10.30M | 286.00K | 755.00K | 7.38M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -554.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 5.51M | 1.43M | 5.52M | 24.29M | 2.84M | 16.24M | 11.95M | 1.62M | 2.44M | 8.71M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 102.33% | 100.00% | 100.00% | 116.02% | 567.48% | 322.91% | 117.99% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 65.03M | 71.08M | 62.99M | 39.05M | 38.66M | 27.84M | 24.84M | 21.32M | 23.37M | 20.48M | 19.64M | 18.93M | 14.78M | 11.92M | 16.50M | 15.82M | 0.00 | 12.58M | 0.00 | 13.68M |
| General & Administrative | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Other Expenses | 1.42M | 1.43M | 882.00K | 582.00K | 762.00K | 314.00K | 209.00K | -61.00K | 86.00K | 38.00K | -1.17M | 278.00K | 284.00K | 233.00K | 218.00K | 283.00K | 0.00 | 982.00K | 0.00 | 22.19M |
| Operating Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Cost & Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.00K | 85.00K | 203.00K | 375.00K | 1.15M | 1.59M | 0.00 | 317.00K | 0.00 | 644.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 243.00K | 0.00 | 0.00 | 94.00K | 1.26M | 0.00 | 964.00K | 0.00 | 135.00K |
| Depreciation & Amortization | 1.42M | 1.43M | 890.00K | 698.00K | 855.00K | 684.00K | 382.00K | 267.00K | 360.00K | 346.00K | 320.00K | 278.00K | 284.00K | 233.00K | 218.00K | 231.00K | 0.00 | 938.00K | 0.00 | 1.80M |
| EBITDA | -75.59M | -85.63M | -77.44M | -44.79M | -25.42M | -33.33M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -20.82M | -11.23M | -15.62M | -18.91M | -20.82M | -1.51K | -12.50M | 0.00 | -30.83M |
| EBITDA Ratio | -1,419.51% | -1,552.97% | -5,407.96% | -811.85% | -107.11% | -1,172.25% | -95.15% | -171.64% | -12,322.73% | -2,355.89% | -245.05% | -130.04% | -124.82% | -706.62% | -609.44% | -677.70% | 0.00% | -347.72% | 0.00% | -1,432.57% |
| Operating Income | -77.01M | -87.06M | -78.33M | -45.49M | -25.05M | -33.28M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -13.78M | -11.51M | -15.62M | -19.09M | -20.82M | -1.51K | -13.97M | 0.00 | -34.78M |
| Operating Income Ratio | -1,446.18% | -1,578.85% | -5,470.11% | -824.51% | -105.51% | -1,170.70% | -92.54% | -166.74% | -10,144.06% | -3,239.34% | -216.82% | -133.22% | -128.77% | -723.25% | -614.88% | -638.50% | 0.00% | -388.49% | 0.00% | -1,616.36% |
| Total Other Income/Expenses | 4.48M | 103.00K | -433.00K | 906.00K | 762.00K | 1.04M | -348.00K | 711.00K | 6.68M | -6.29M | 1.27M | 34.00K | 134.00K | 249.00K | 1.10M | -3.57M | -52.00K | -233.00K | 0.00 | -1.08M |
| Income Before Tax | -72.53M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.37M | -16.46M | -22.34M | -30.74M | -14.74M | -24.39M | -11.38M | -17.99M | -17.99M | -24.39M | 0.00 | -14.20M | 0.00 | -35.86M |
| Income Before Tax Ratio | -1,362.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.68% | -159.84% | -7,809.44% | -4,071.92% | -199.66% | -235.74% | -127.27% | -833.35% | -579.45% | -748.01% | 0.00% | -394.97% | 0.00% | -1,666.36% |
| Income Tax Expense | -4.47M | 0.00 | 0.00 | 0.00 | 762.00K | -728.00K | -37.00K | -38.00K | -253.00K | 6.32M | -2.44M | -34.00K | -134.00K | -249.00K | -1.10M | -1.84M | 1.51K | 924.00K | 0.00 | -547.00K |
| Net Income | -68.06M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.34M | -16.42M | -22.08M | -30.74M | -14.74M | -13.75M | -11.38M | -15.37M | -17.99M | -18.93M | -1.51K | -14.60M | 0.00 | -33.16M |
| Net Income Ratio | -1,278.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.45% | -159.47% | -7,720.98% | -4,071.92% | -199.66% | -132.89% | -127.27% | -711.72% | -579.45% | -580.55% | 0.00% | -405.98% | 0.00% | -1,540.94% |
| EPS | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -5.00 | -7.17 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| EPS Diluted | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -4.96 | -7.03 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| Weighted Avg Shares Out | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.29M | 3.08M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
| Weighted Avg Shares Out (Dil) | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.31M | 3.14M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
Athersys (ATHX) Stock: Why The Price Jumped Today
The stock price of Athersys Inc (NASDAQ: ATHX) increased by over 15% pre-market today. This is why it happened.
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Publication of Athersys clinical trial results show MultiStem cell therapy support potential benefits for ARDS patients, including lower mortality.
Athersys: COVID-ARDS Is The Company's Most Important Target
I covered Athersys' ischemic stroke trial earlier.
Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Athersys, Inc. (ATHX) CEO B.J. Lehmann on Q3 2021 Results - Earnings Call Transcript
Athersys, Inc. (ATHX) CEO B.J. Lehmann on Q3 2021 Results - Earnings Call Transcript
Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2021 and provided a corporate update. “The third quarter brought several important milestones in the development and potential commercialization of MultiStem® cell therapy,”...
Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Positive topline data for ARDS study announced and countdown begins to the release of pivotal stroke study data for MultiStem cell therapy.
Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys reports its partner Healios provided an update regarding its clinical programs for ARDS and ischemic stroke involving MultiStem cell therapy.
Athersys to Host Third Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the...
Source: https://incomestatements.info
Category: Stock Reports